Association of KRAS and EGFR Mutations With Survival in Patients With Advanced Lung AdenocarcinomasJOHNSON, Melissa L; SIMA, Camelia S; CHAFT, Jamie et al.Cancer. 2013, Vol 119, Num 2, pp 356-362, issn 0008-543X, 7 p.Article

Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 MutationsREKHTMAN, Natasha; PAIK, Paul K; ARCILA, Maria E et al.Clinical cancer research (Print). 2012, Vol 18, Num 4, pp 1167-1176, issn 1078-0432, 10 p.Article

A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignanciesPAIK, Paul K; RUDIN, Charles M; TYSON, Leslie et al.Cancer chemotherapy and pharmacology. 2010, Vol 66, Num 6, pp 1079-1085, issn 0344-5704, 7 p.Article

Driver Mutations Determine Survival in Smokers and Never-Smokers With Stage IIIB/IV Lung AdenocarcinomasPAIK, Paul K; JOHNSON, Melissa L; D'ANGELO, Sandra P et al.Cancer. 2012, Vol 118, Num 23, pp 5840-5847, issn 0008-543X, 8 p.Article

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant CancersDOGAN, Snjezana; RONGLAI SHEN; LADANYI, Marc et al.Clinical cancer research (Print). 2012, Vol 18, Num 22, pp 6169-6177, issn 1078-0432, 9 p.Article

A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancerPAIK, Paul K; RUDIN, Charles M; MARKUS, Susan et al.Lung cancer. 2011, Vol 74, Num 3, pp 481-485, issn 0169-5002, 5 p.Article

Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumabHELLMANN, Matthew D; CHAFT, Jamie E; KRUG, Lee M et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 2, pp 453-461, issn 0344-5704, 9 p.Article

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung AdenocarcinomasARCILA, Maria E; CHAFT, Jamie E; NAFA, Khedoudja et al.Clinical cancer research (Print). 2012, Vol 18, Num 18, pp 4910-4918, issn 1078-0432, 9 p.Article

A phase 2 study of weekly albumin-bound paclitaxel (Abraxane^®) given as a two-hour infusionPAIK, Paul K; JAMES, Leonard P; RIZVI, Naiyer A et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 5, pp 1331-1337, issn 0344-5704, 7 p.Article

Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF MutationsPAIK, Paul K; ARCILA, Maria E; FARA, Michael et al.Journal of clinical oncology. 2011, Vol 29, Num 15, pp 2046-2051, issn 0732-183X, 6 p.Article